Sonnet BioTherapeutics Holdings, Inc.
SONN
$1.36
-$0.01-0.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 142.59% | -356.46% | |||
| Gross Profit | -120.01% | 356.46% | |||
| SG&A Expenses | -0.57% | 9.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.30% | -10.07% | |||
| Operating Income | 10.21% | 10.07% | |||
| Income Before Tax | 4.04% | 10.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.03% | 10.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.03% | 10.75% | |||
| EBIT | 10.21% | 10.07% | |||
| EBITDA | 10.22% | 10.08% | |||
| EPS Basic | 53.04% | 40.23% | |||
| Normalized Basic EPS | 55.40% | 40.23% | |||
| EPS Diluted | 53.04% | 40.23% | |||
| Normalized Diluted EPS | 55.40% | 40.23% | |||
| Average Basic Shares Outstanding | 115.12% | 49.33% | |||
| Average Diluted Shares Outstanding | 115.12% | 49.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||